CRISPR's Promise Meets Market Reality: First Gene-Editing Drugs to Cost $3M

Fyodor Urnov receives messages that break him. Parents, siblings, grandparents of children dying from genetic diseases write to ask if he can save them. "My small angel is going to die," they tell him. "You have children too, so you must understand what we are going through." There are roughly six thousand rare genetic diseases caused by mutations in human DNA, and while each is uncommon in isolation, they affect approximately three hundred million people worldwide—nearly the entire population of the United States. Urnov, now fifty-five, born in Moscow to a linguist mother and book editor father, has spent his career trying to answer those desperate letters. In 2005, his team became the first to edit the genome of human cells, correcting a mutation that causes severe combined immunodeficiency—a condition fatal within months if untreated. That work proved the human genome, with its three billion letters of genetic code, was not sacred scripture but editable text. He called it "genome editing."

The field has moved with stunning speed. The tool Urnov used then, zinc finger nucleases, was crude compared to CRISPR, a molecule that emerged seven years later and could rewrite any organism's genetic code with remarkable ease. "If someone had told me then that in 2023 we would be seeing the first gene-editing drugs arrive, I would have told them to take a cold shower," Urnov says now, directing the Innovative Genomics Institute at the University of California. Yet here they are. This year, the first CRISPR-based therapies will receive regulatory approval. They will also cost three million dollars per patient—nearly as much as the world's most expensive drug currently on the market.

This is the paradox that haunts Urnov's work. The technology exists to cure diseases that have no other treatment. A young patient he knows has a genetic condition that will blind her. He knows how to repair it genetically. But in practice, developing a therapy for her specific mutation requires five to ten million dollars and at least four years of work—a treatment for one person, one mutation. By the time it exists, she will have lost her sight. The problem is not scientific. It is systemic. We have perfected technology from 2023, Urnov explains, but we are operating within a development system from 2003. CRISPR works. Sequencing works. Drug delivery works. What does not work is the economics. Biotech companies need investors to recoup their money. They cannot afford to spend ten million dollars developing a drug for a single patient. They develop therapies they can sell. CRISPR Therapeutics, seeking approval this year for the first CRISPR-based treatment, will charge three million dollars because the company must return its investors' capital. That part of the system functions perfectly. The problem is that millions of patients who could be cured will not be.

The first approved therapies will treat sickle cell disease and beta-thalassemia, blood disorders where CRISPR-edited cells must be manufactured in production facilities, then reinjected into patients alongside chemotherapy and extended hospitalization. The cost reflects this complexity. But newer approaches using injectable CRISPR—packaged as messenger RNA inside lipid nanoparticles, the same delivery method that made COVID vaccines manufacturable at scale—could reduce costs tenfold. The technology is advancing. The system is not.

Urnov proposes something radical: countries or coalitions of nations should develop CRISPR cures for rare genetic diseases as a collective project, not waiting for pharmaceutical companies to solve a problem that offers no profit motive. The ethical argument is straightforward. But there is also precedent. Statins were developed using a futuristic approach to treat a rare cardiovascular disease. Clinical trials proved they worked. Later, doctors gave them to patients with common heart conditions. They worked there too. If CRISPR therapies prove safe and effective in ten patients with rare brain, lung, or liver diseases, those same cures might later expand to treat Alzheimer's disease, chronic obstructive pulmonary disease, or fatty liver disease—conditions affecting millions. The rare disease becomes the proof of concept for the common one.

This year, the first two CRISPR therapies will likely be approved in the United States, probably followed soon by the European Union. They target blood disorders and are ideally suited for children, where early correction prevents lifelong suffering. Companies are already running clinical trials with pediatric patients. In 2024, therapies for rare liver diseases—transthyretin amyloidosis and hereditary angioedema—will probably follow. But whether a person in Spain with an inherited blood disorder will ever walk into a hospital and receive CRISPR treatment remains unknown. The technology is ready. The system that delivers it is not. Urnov believes progress will be impressive—therapies for immune disorders like rheumatoid arthritis, then metabolic liver diseases, eventually the lungs and nervous system. Each advance teaches the next. But he will not promise more than he knows is possible. The gap between what medicine can do and what patients can access has never been wider.